Biotech start-up Pretzel Therapeutics launched Monday with $72.5 million in Series A financing to develop novel, mitochondria-based therapies for rare genetic disorders and diseases of aging.
Pretzel plans to target mitochondrial diseases, a highly heterogenous group of conditions caused by DNA mutations in the mitochondria or the nucleus. These disorders are very rare, afflicting around one in 5,000 people.
Pretzel CEO Jay Parrish told BioSpace the funding “should enable us to get close to the clinic if not into the clinic with one or more programs.”
Comments are closed.